The role of microRNA in cisplatin resistance or sensitivity

Shanshan Wang,Ming-Yue Li,Yi Liu,Alexander C Vlantis,Jason YK Chan,Lingbin Xue,Bao-Guang Hu,Shucai Yang,Mo-Xian Chen,Shaoming Zhou,Wei Guo,Xianhai Zeng,Shuqi Qiu,C Andrew van Hasselt,Michael CF Tong,George G Chen

DOI: https://doi.org/10.1080/14728222.2020.1785431

IF: 6.797

2020-07-07

Expert Opinion on Therapeutic Targets

Abstract:Cisplatin is a chemotherapy drug that has been used to treat a number of cancers for decades, and is still one of the most commonly used anti-cancer agents. However, some patients do not respond to cisplatin while other patients who were originally sensitive to cisplatin eventually develop chemoresistance, leading to treatment failure or/and tumor recurrence.Different mechanisms contribute to cisplatin resistance or sensitivity, involving multiple pathways or/and processes such as DNA repair, DNA damage response, drug transport, and apoptosis. Among the various mechanisms, it appears that microRNAs play an important role in determining the resistance or sensitivity. In this article, we analyzed and summarized recent findings in this area, with the aim that these data can aid further research and understanding, leading to the eventual reduction of cisplatin resistance.microRNAs can positively or negatively regulate cisplatin resistance by acting on molecules or/and pathways related to apoptosis, autophagy, hypoxia, cancer stem cells, NF-κB, and Notch1. It appears that the modulation of relevant microRNAs can effectively re-sensitize cancer cells to cisplatin regimen in certain types of cancers including breast, colorectal, gastric, liver, lung, ovarian, prostate, testicular, and thyroid cancers.

pharmacology & pharmacy

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the resistance to cisplatin in cancer treatment. Cisplatin is a commonly used chemotherapeutic drug for treating various types of cancers, such as breast cancer, gastric cancer, lung cancer, ovarian cancer, testicular cancer, head and neck cancer, and thyroid cancer. However, in clinical applications, some patients do not respond to cisplatin, or patients who were originally sensitive to cisplatin eventually develop resistance, leading to treatment failure or tumor recurrence. This has become a major challenge in current clinical practice.

To overcome this challenge, researchers have focused on the role of microRNA (miRNA) in cisplatin resistance and sensitivity. miRNA is a class of small non - coding RNA molecules that function by post - transcriptional regulation of gene expression and can act as tumor suppressors or oncogenes. Studies have found that miRNA can positively or negatively regulate cisplatin resistance by acting on molecules or pathways related to apoptosis, autophagy, hypoxia, cancer stem cells, NF - κB, and Notch1, etc.

Therefore, the main purpose of this paper is to summarize and analyze the research progress in recent years on the role of miRNA in cisplatin resistance and sensitivity, hoping that these data can provide help for further research and understanding, and ultimately reduce cisplatin resistance and improve treatment efficacy. The paper also discusses the possibility of combining cisplatin with other anti - tumor agents (including miRNA) to reduce tumor resistance.